Literature DB >> 17393978

Phenotype-directed analysis of genotype in early-onset, familial breast cancers.

Gareth R Price1, Jane E Armes, Susan J Ramus, Elena Provenzano, Beena Kumar, Tiffany F Cowie, John Ciciulla, Anne-Marie Hutchins, Mervyn Thomas, Deon J Venter.   

Abstract

UNLABELLED: Considerable heterogeneity of morphology and disease outcome exists within breast cancers (BC), which likely reflects variable molecular pathogeneses within this broad clinical group. AIM: To evaluate the underlying genomic alterations associated with familial, early-onset BC (EOBC) phenotypes, in order to improve the management of this disease.
METHODS: Using hierarchical clustering of morphological and immunophenotypical parameters, 116 EOBC were stratified into six groups. Conventional and array-based comparative genomic hybridisation was used to analyse the genomic alterations.
RESULTS: Specific areas of genomic imbalance were associated with individual phenotypes. The largest phenotypical group was high grade, oestrogen receptor and HER-2 negative. This group contained the majority of BRCA1 germline mutation-associated tumours and commonly showed loss of chromosomal regions 5cent-5q13, 5q14-22 and 4q28-32. High mitotic rate, an important indicator of tumour cell proliferation and poor prognosis, was associated with gain of 19p, mapped within 7 Mb of the telomere. This region contains the candidate oncogene CDC34, the protein product of which is involved in ubiquitin-mediated degradation of the cyclin-dependent kinase inhibitor, p27Kip1.
CONCLUSION: Phenotype-based analysis can be used to determine the genetic changes important in subtypes of BC. Further, the different morphological phenotypes could act as a cost-effective surrogate for genotypical stratification to facilitate optimal management of this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17393978     DOI: 10.1080/00313020601024052

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  5 in total

1.  Oxidative stress responses involve oxidation of a conserved ubiquitin pathway enzyme.

Authors:  Kathryn S Doris; Ellen L Rumsby; Brian A Morgan
Journal:  Mol Cell Biol       Date:  2012-09-04       Impact factor: 4.272

2.  Structural insights into E1 recognition and the ubiquitin-conjugating activity of the E2 enzyme Cdc34.

Authors:  Katelyn M Williams; Shuo Qie; James H Atkison; Sabrina Salazar-Arango; J Alan Diehl; Shaun K Olsen
Journal:  Nat Commun       Date:  2019-07-24       Impact factor: 14.919

3.  Inhibitors of the Cdc34 acidic loop: A computational investigation integrating molecular dynamics, virtual screening and docking approaches.

Authors:  Alberto Arrigoni; Luca Bertini; Luca De Gioia; Elena Papaleo
Journal:  FEBS Open Bio       Date:  2014-05-09       Impact factor: 2.693

4.  Targeting CDC34 E2 ubiquitin conjugating enzyme for lung cancer therapy.

Authors:  Shizhen Zhang; Yi Sun
Journal:  EBioMedicine       Date:  2020-04-05       Impact factor: 8.143

5.  Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis.

Authors:  Xin-Chun Zhao; Gui-Zhen Wang; Zhe-Sheng Wen; Yong-Chun Zhou; Qian Hu; Bin Zhang; Li-Wei Qu; San-Hui Gao; Jie Liu; Liang Ma; Yan-Fei Zhang; Chen Zhang; Hong Yu; Da-Lin Zhang; Min Wang; Chang-Li Wang; Yun-Chao Huang; Zhi-Hua Liu; Yong Zhao; Liang Chen; Guang-Biao Zhou
Journal:  EBioMedicine       Date:  2020-02-27       Impact factor: 8.143

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.